Filing Details
- Accession Number:
- 0001140361-24-047697
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-11-22 21:00:12
- Reporting Period:
- 2024-11-20
- Accepted Time:
- 2024-11-22 21:00:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1635088 | Roivant Sciences Ltd. | ROIV | Pharmaceutical Preparations (2834) | 981173944 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1801917 | Eric Venker | C/O Roivant Sciences Ltd. 7Th Floor, 50 Broadway London X0 SW1H 0DB | President & Coo | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Disposition | 2024-11-20 | 10,945 | $11.49 | 606,525 | No | 4 | F | Direct | |
| Common Shares | Acquisiton | 2024-11-20 | 100,000 | $3.85 | 706,525 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2024-11-20 | 100,000 | $11.32 | 606,525 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2024-11-20 | 100,000 | $0.00 | 100,000 | $3.85 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 12,326,234 | 2032-04-19 | No | 4 | M | Direct |
Footnotes
- Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
- The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 25, 2024.
- Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).
Billionaire Hedge Funds
